Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Recommendation of “Buy” by Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been given an average rating of “Buy” by the eleven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $16.5556.

Several equities analysts have recently issued reports on IVA shares. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Cantor Fitzgerald started coverage on shares of Inventiva in a research note on Friday. They issued an “overweight” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st.

Inventiva Trading Up 2.2%

NASDAQ:IVA opened at $4.62 on Friday. The firm’s 50 day simple moving average is $4.36 and its 200 day simple moving average is $5.32. Inventiva has a one year low of $2.85 and a one year high of $7.98.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG lifted its stake in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after acquiring an additional 2,634,580 shares during the period. Propel Bio Management LLC bought a new stake in Inventiva in the fourth quarter valued at approximately $4,650,000. Eventide Asset Management LLC acquired a new stake in Inventiva during the 4th quarter valued at approximately $1,155,000. NEXTBio Capital Management LP acquired a new stake in Inventiva during the 4th quarter valued at approximately $6,039,000. Finally, Simplify Asset Management Inc. bought a new position in Inventiva during the 4th quarter worth approximately $1,570,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.